U.S. Markets closed

Rigel Pharmaceuticals, Traction from TAVALISSE(TM) Sales and Pipeline, Analysts Review and Target

NEW YORK, NY / ACCESSWIRE / August 30, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Rigel Pharmaceuticals, Inc., (RIGL), a biotechnology company developing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.

On May 29, Rigel launched TAVALISSE™ (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to previous treatment.

Analysts review, target and potential near-term catalysts in this comprehensive report READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/rigel-pharmaceuticals-3/

As per management, the company is now communicating TAVALISSE's value proposition to patients, physicians, and payers: namely, its unique mechanism of action that targets an underlying cause of the disease, efficacy, oral dosing, safety profile, and comprehensive patient support and access programs.

The company continues to make pipeline progress that it expects will leverage the commercial capabilities it now has in place.

Review the company pipeline products and financial data here READ MORE

Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/rigel-pharmaceuticals-3/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source